Chronic Venous Insufficiency - Epidemiology Forecast - 2034
Description
Key Highlights
Chronic venous insufficiency (CVI) is a common but underdiagnosed condition caused by dysfunction of the venous valves, leading to venous hypertension and abnormalities in the leg. The impaired valve function hinders the normal reduction in venous pressure that occurs during physical activity, leading to a buildup of blood in the affected veins.
In EU4 and the UK, the total diagnosed prevalent cases of CVD were 34,104,300 approximately in 2020. Of these, most of the cases were found in Germany, followed by Italy and the UK. These cases are expected to increase during the study period.
In the 7MM, the total diagnosed prevalent cases of CVI were 17,641,600 approximately in 2020, which is expected to increase at a CAGR of 1.4% by 2034.
CVI is possibly slightly more common in women compared to men.
In 2023, the total diagnosed prevalent cases of CVI in Japan were around 3 million cases, and these cases are expected to increase during the forecast period.
DelveInsight’s “Chronic Venous Insufficiency – Epidemiology – 2034” report delivers an in-depth understanding of CVI, historical and forecasted epidemiology of CVI in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Geography Covered
The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
Study Period: 2020–2034
Chronic Venous Insufficiency Disease Understanding
CVI Overview
CVD is a prevalent medical condition affecting the venous system, particularly the veins in the lower extremities. It encompasses a spectrum of venous disorders, ranging from mild cosmetic concerns like spider veins to severe and debilitating conditions like venous ulcers. CVI refers to the more advanced stages of CVD, which is a globally prevalent long-term condition in which the impaired blood flow in either superficial or deep veins, leads to increased venous pressure, known as venous hypertension. This condition manifests through various pathological changes, including swelling in the lower extremities, skin changes, and discomfort, all due to elevated venous pressure.
CVI Diagnosis
Diagnosing chronic venous insufficiency (CVI) relies on clinical features and diagnostic studies, with venous duplex ultrasound being the primary tool for providing detailed information on blood flow and venous anatomy. Clinical symptoms include edema, leg discomfort, varicose veins, and skin changes like hyperpigmentation and ulceration. Additional diagnostic techniques include phlebography, air plethysmography, phlebodynamometry, color-flow duplex ultrasound, and physical examination, all contributing to a comprehensive diagnosis. Differential diagnosis is essential to distinguish CVI from conditions like deep vein thrombosis, lymphedema, and systemic causes of edema, ensuring accurate treatment and preventing complications. A thorough medical history and physical examination are crucial for guiding appropriate treatment and improving patient outcomes.
Further details related to diagnosis are provided in the report…
Chronic Venous Insufficiency Epidemiology
The CVI epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by the
total prevalent cases of CVD, total diagnosed prevalent cases for CVD, stage-specific diagnosed prevalent cases of CVD, diagnosed prevalent cases of CVI, gender-specific prevalent cases of Chronic Venous Insufficiency, and total treated cases of Chronic Venous Insufficiency in the 7MM market covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.
In the US, there were 52,097,119 total diagnosed prevalent cases of CVD in 2020; which are expected to increase at a CAGR of 1.6% to 64,930,445 by 2034.
In 2023 in the United States, there were more prevalent cases of CVI among females than number of male cases.
In the US, CVI shows a marked gender disparity, with females accounting for 77.99% of cases compared to 22.01% in males.
KOL Views
To keep up with current epidemiology trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on the CVI evolving epidem landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility including Physicians and others.
DelveInsight’s analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the University of California, University of Michigan, Washington Hospital Healthcare System, University Hospital Münster, Germany etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or CVI epidem trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the epidem and the unmet needs.
Scope of the Report
The report covers a segment of key events, an executive summary, descriptive overview of CVI, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
Comprehensive insight into the epidemiology segments and forecasts and disease progression has been provided.
The report provides an edge while developing business strategies, understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
A detailed review of current challenges in establishing the diagnosis.
Chronic Venous Insufficiency Report Insights
Prevalent Cases of CVD
Diagnosed Prevalent Cases for CVD
Stage-specific Diagnosed Prevalent Cases of CVD
Diagnosed Prevalent Cases of CVI
Gender-specific Diagnosed Prevalent Cases of CVI
Chronic Venous Insufficiency Report Key Strengths
Eleven Years Forecast
The 7MM Coverage
CVI Epidemiology Segmentation
Chronic Venous Insufficiency Report Assessment
Current Diagnostic Practices
Epidemiology Insights
What are the disease risks, burdens, and unmet needs of CVI? What will be the growth opportunities across the 7MM concerning the patient population with CVI?
What is the historical and forecasted CVI patient pool in the United States, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan?
Which age group of CVI has a high patient share?
Reasons to Buy
Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand the age-specific CVI prevalence cases in varying geographies over the coming years.
To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the treatment-eligible patient pool.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Chronic venous insufficiency (CVI) is a common but underdiagnosed condition caused by dysfunction of the venous valves, leading to venous hypertension and abnormalities in the leg. The impaired valve function hinders the normal reduction in venous pressure that occurs during physical activity, leading to a buildup of blood in the affected veins.
In EU4 and the UK, the total diagnosed prevalent cases of CVD were 34,104,300 approximately in 2020. Of these, most of the cases were found in Germany, followed by Italy and the UK. These cases are expected to increase during the study period.
In the 7MM, the total diagnosed prevalent cases of CVI were 17,641,600 approximately in 2020, which is expected to increase at a CAGR of 1.4% by 2034.
CVI is possibly slightly more common in women compared to men.
In 2023, the total diagnosed prevalent cases of CVI in Japan were around 3 million cases, and these cases are expected to increase during the forecast period.
DelveInsight’s “Chronic Venous Insufficiency – Epidemiology – 2034” report delivers an in-depth understanding of CVI, historical and forecasted epidemiology of CVI in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Geography Covered
The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
Study Period: 2020–2034
Chronic Venous Insufficiency Disease Understanding
CVI Overview
CVD is a prevalent medical condition affecting the venous system, particularly the veins in the lower extremities. It encompasses a spectrum of venous disorders, ranging from mild cosmetic concerns like spider veins to severe and debilitating conditions like venous ulcers. CVI refers to the more advanced stages of CVD, which is a globally prevalent long-term condition in which the impaired blood flow in either superficial or deep veins, leads to increased venous pressure, known as venous hypertension. This condition manifests through various pathological changes, including swelling in the lower extremities, skin changes, and discomfort, all due to elevated venous pressure.
CVI Diagnosis
Diagnosing chronic venous insufficiency (CVI) relies on clinical features and diagnostic studies, with venous duplex ultrasound being the primary tool for providing detailed information on blood flow and venous anatomy. Clinical symptoms include edema, leg discomfort, varicose veins, and skin changes like hyperpigmentation and ulceration. Additional diagnostic techniques include phlebography, air plethysmography, phlebodynamometry, color-flow duplex ultrasound, and physical examination, all contributing to a comprehensive diagnosis. Differential diagnosis is essential to distinguish CVI from conditions like deep vein thrombosis, lymphedema, and systemic causes of edema, ensuring accurate treatment and preventing complications. A thorough medical history and physical examination are crucial for guiding appropriate treatment and improving patient outcomes.
Further details related to diagnosis are provided in the report…
Chronic Venous Insufficiency Epidemiology
The CVI epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by the
total prevalent cases of CVD, total diagnosed prevalent cases for CVD, stage-specific diagnosed prevalent cases of CVD, diagnosed prevalent cases of CVI, gender-specific prevalent cases of Chronic Venous Insufficiency, and total treated cases of Chronic Venous Insufficiency in the 7MM market covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.
In the US, there were 52,097,119 total diagnosed prevalent cases of CVD in 2020; which are expected to increase at a CAGR of 1.6% to 64,930,445 by 2034.
In 2023 in the United States, there were more prevalent cases of CVI among females than number of male cases.
In the US, CVI shows a marked gender disparity, with females accounting for 77.99% of cases compared to 22.01% in males.
KOL Views
To keep up with current epidemiology trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on the CVI evolving epidem landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility including Physicians and others.
DelveInsight’s analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the University of California, University of Michigan, Washington Hospital Healthcare System, University Hospital Münster, Germany etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or CVI epidem trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the epidem and the unmet needs.
Scope of the Report
The report covers a segment of key events, an executive summary, descriptive overview of CVI, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
Comprehensive insight into the epidemiology segments and forecasts and disease progression has been provided.
The report provides an edge while developing business strategies, understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
A detailed review of current challenges in establishing the diagnosis.
Chronic Venous Insufficiency Report Insights
Prevalent Cases of CVD
Diagnosed Prevalent Cases for CVD
Stage-specific Diagnosed Prevalent Cases of CVD
Diagnosed Prevalent Cases of CVI
Gender-specific Diagnosed Prevalent Cases of CVI
Chronic Venous Insufficiency Report Key Strengths
Eleven Years Forecast
The 7MM Coverage
CVI Epidemiology Segmentation
Chronic Venous Insufficiency Report Assessment
Current Diagnostic Practices
Epidemiology Insights
What are the disease risks, burdens, and unmet needs of CVI? What will be the growth opportunities across the 7MM concerning the patient population with CVI?
What is the historical and forecasted CVI patient pool in the United States, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan?
Which age group of CVI has a high patient share?
Reasons to Buy
Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand the age-specific CVI prevalence cases in varying geographies over the coming years.
To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the treatment-eligible patient pool.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Table of Contents
85 Pages
- 1. KEY INSIGHTS
- 2. REPORT INTRODUCTION
- 3. EXECUTIVE SUMMARY OF CVI
- 4. EPIDEMIOLOGY METHODOLOGY
- 5. CVI EPIDEMIOLOGY OVERVIEW AT A GLANCE IN THE 7MM
- 5.1. Patient Share (%) Distribution of CVI in 2020
- 5.2. Patient Share (%) Distribution of CVI in 2034
- 6. DISEASE BACKGROUND AND OVERVIEW
- 6.1. INTRODUCTION
- 6.2. Classification of CVI
- 6.3. Signs and Symptoms of CVI
- 6.4. Causes of CVI
- 6.5. Pathophysiology
- 6.6. Diagnosis
- 6.6.1. Diagnostic Guidelines
- 7. EPIDEMIOLOGY AND PATIENT POPULATION
- 7.1. Key Findings
- 7.2. Assumption and Rationale
- 7.3. Total Diagnosed Prevalent Cases of CVI in the 7MM
- 7.4. The United States
- 7.4.1. Total Prevalent Cases of CVD in the United States
- 7.4.2. Total Diagnosed Prevalent Cases of CVD in the United States
- 7.4.3. Stage-specific Cases of CVD in the United States
- 7.4.4. Total Diagnosed Prevalent Cases of CVI in the United States
- 7.4.5. Gender-specific Cases of CVI in the United S
- 7.5. EU4 and the UK
- 7.5.1. Total Prevalent Cases of CVD in EU4 and the UK
- 7.5.2. Total Diagnosed Prevalent Cases of CVD in the EU4 and the UK
- 7.5.3. Stage-specific Cases of CVD in the EU4 and the UK
- 7.5.4. Total Diagnosed Prevalent Cases of CVI in the EU4 and the UK
- 7.5.5. Gender-specific Cases of CVI in the EU4 and the UK
- 7.7. Japan
- 7.7.1. Total Prevalent Cases of CVI in Japan
- 7.7.2. Total Diagnosed Prevalent Cases of CVD in the Japan
- 7.7.3. Stage-specific Cases of CVD in the Japan
- 7.7.4. Total Diagnosed Prevalent Cases of CVI in the Japan
- 7.7.5. Gender-specific Cases of CVI in the EU4 and the Japan.
- 8. Appendix
- 8.1. BIBLIOGRAPHY
- 8.2. REPORT METHODOLOGY
- 9. DelveInsight Capabilities
- 10. Disclaimer
- 11. About DelveInsight
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
